Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company’s lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Metrics to compare | TECX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTECXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.5x | −5.7x | −0.6x | |
PEG Ratio | −0.09 | 0.02 | 0.00 | |
Price/Book | 1.4x | 7.0x | 2.6x | |
Price / LTM Sales | - | 12.7x | 3.4x | |
Upside (Analyst Target) | 288.0% | 92.7% | 40.2% | |
Fair Value Upside | Unlock | −14.3% | 4.8% | Unlock |